iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Purchased by nVerses Capital LLC

nVerses Capital LLC raised its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 212.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,500 shares of the company’s stock after acquiring an additional 1,700 shares during the quarter. nVerses Capital LLC’s holdings in iTeos Therapeutics were worth $26,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ITOS. The Manufacturers Life Insurance Company increased its stake in shares of iTeos Therapeutics by 6.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,071 shares of the company’s stock valued at $164,000 after purchasing an additional 690 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in iTeos Therapeutics by 35.9% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after purchasing an additional 3,172 shares during the period. SG Americas Securities LLC purchased a new stake in shares of iTeos Therapeutics in the third quarter valued at approximately $126,000. Creative Planning raised its stake in shares of iTeos Therapeutics by 6.5% during the 3rd quarter. Creative Planning now owns 19,636 shares of the company’s stock worth $200,000 after buying an additional 1,196 shares during the period. Finally, Los Angeles Capital Management LLC acquired a new position in shares of iTeos Therapeutics during the 1st quarter worth approximately $401,000. Hedge funds and other institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Stock Down 1.6 %

Shares of ITOS opened at $8.85 on Thursday. iTeos Therapeutics, Inc. has a 52-week low of $8.63 and a 52-week high of $18.75. The stock has a market cap of $319.69 million, a PE ratio of -2.34 and a beta of 1.36. The firm’s fifty day moving average is $13.03 and its two-hundred day moving average is $14.31.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.86. The business had revenue of $35.00 million for the quarter, compared to analyst estimates of $4.20 million. As a group, research analysts anticipate that iTeos Therapeutics, Inc. will post -3.64 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on ITOS. JPMorgan Chase & Co. dropped their price target on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th. Wells Fargo & Company assumed coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They set an “overweight” rating and a $31.00 target price for the company. HC Wainwright restated a “buy” rating and set a $46.00 price target on shares of iTeos Therapeutics in a research report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $21.00 price objective on shares of iTeos Therapeutics in a report on Thursday, August 8th.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.